Human Genome Epidemiology Literature Finder
Pharmacogenomics
Records 1 - 30 (of 589 Records) |
Query Trace: Irinotecan[original query] |
---|
Incidence of and risk factors for severe neutropenia during treatment with the modified FOLFIRINOX therapy in patients with advanced pancreatic cancer. Scientific reports 2022 9 12 (1): 15574. Irisawa Ai, Takeno Misaki, Watanabe Kazuo, Takahashi Hideaki, Mitsunaga Shuichi, Ikeda Masafu |
Bilirubin metabolism and UDP-glucuronosyltransferase 1A1 variants in Asians: Pathogenic implications and therapeutic response. The Kaohsiung journal of medical sciences 2022 8 38 (8): 729-738. Huang May-Jen, Chen Pei-Lain, Huang Ching-Sh |
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM). ESMO open 2022 8 7 (5): 100567. Ciardiello D, Chiarazzo C, Famiglietti V, Damato A, Pinto C, Zampino M G, Castellano G, Gervaso L, Zaniboni A, Oneda E, Rapisardi S, Bordonaro R, Zichi C, De Vita F, Di Maio M, Parisi A, Giampieri R, Berardi R, Lavacchi D, Antonuzzo L, Tamburini E, Maiorano B A, Parrella P, Latiano T P, Normanno N, De Stefano A, Avallone A, Martini G, Napolitano S, Troiani T, Martinelli E, Ciardiello F, De Vita F, Maiello |
Risk Factors for Septic Shock After Irinotecan-Containing Chemotherapy: An Exploratory Case-Control Study. Drugs in R&D 2022 Aug . Umemiya Maki, Inayama Yoshihide, Nakatani Eiji, Ito Kenta, Tsuji Mitsuru, Yoshida Teruki, Yu Sae, Gou Rei, Horikawa Naoki, Tani Hirohiko, Kosaka Ken |
Response to letter entitled re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients: Is it time for everyone treated with irinotecan to be tested for UGT1A1 gene polymorphism? European journal of cancer (Oxford, England : 1990) 2022 Jul 172 231-233. Hulshof Emma C, de With Mirjam, Creemers Geert-Jan, Guchelaar Henk-Jan, Mathijssen Ron Hj, Gelderblom Hans, Deenen Maarten |
Alterations in Somatic Driver Genes Are Associated with Response to Neoadjuvant FOLFIRINOX in Patients with Localized Pancreatic Ductal Adenocarcinoma. Journal of the American College of Surgeons 2022 7 235 (2): 342-349. Ecker Brett L, Court Colin M, Janssen Quisette P, Tao Alice J, D'Angelica Michael I, Drebin Jeffrey A, Gonen Mithat, O'Reilly Eileen M, Jarnagin William R, Wei Alice C, |
Re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients: Is it time for everyone treated with irinotecan to be tested for UGT1A1 gene polymorphism? European journal of cancer (Oxford, England : 1990) 2022 Jul 170 194-195. Kong Lingti, Rong Li, Wang Muh |
Rapid detection of the irinotecan-related UGT1A1*28 polymorphism by asymmetric PCR melting curve analysis using one fluorescent probe. Journal of clinical laboratory analysis 2022 6 36 (8): e24578. Kong Xiaomu, Xu Ye, Gao Peng, Liu Yi, Wang Xuran, Zhao Meimei, Jiang Yongwei, Yang Hui, Cao Yongtong, Ma Lia |
Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of first-line FOLFOXIRI plus bevacizumab for RAS-mutant metastatic colorectal cancer (JACCRO CC-11). ESMO open 2022 6 7 (3): 100512. Sunakawa Y, Satake H, Usher J, Jaimes Y, Miyamoto Y, Nakamura M, Kataoka M, Shiozawa M, Takagane A, Terazawa T, Watanabe T, Ishiguro K, Tanaka C, Takeuchi M, Fujii M, Danenberg K, Danenberg P V, Lenz H-J, Sekikawa T, Ichikawa |
Optimizing Chemotherapy of Pancreatic Acinar Cell Carcinoma: Our Experiences and Pooled Analysis of Literature. Clinical Medicine Insights. Oncology 2022 5 16 11795549221090186. Xu Jian-Ying, Guan Wen-Long, Lu Shi-Xun, Wei Xiao-Li, Shi Wen-Jie, Ren Chao, Li Yu-Hong, Li Sheng-Ping, Qiu Miao-Zhen, Wang Feng-H |
Association of UGT1A1*6, UGT1A1*28, or ABCC2 c.3972C>T genetic polymorphisms with irinotecan-induced toxicity in Asian cancer patients: Meta-analysis. Clinical and translational science 2022 May . Atasilp Chalirmporn, Biswas Mohitosh, Jinda Pimonpan, Nuntharadthanaphong Nutthan, Rachanakul Jiratha, Hongkaew Yaowaluck, Vanwong Natchaya, Saokaew Surasak, Sukasem Chonlaph |
Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO study. Thoracic cancer 2023 9 . Hiromi Tomono, Hirokazu Taniguchi, Minoru Fukuda, Takaya Ikeda, Seiji Nagashima, Kazumasa Akagi, Sawana Ono, Yasuhiro Umeyama, Midori Shimada, Hiroshi Gyotoku, Shinnosuke Takemoto, Yasushi Hisamatsu, Ryotaro Morinaga, Ryuta Tagawa, Ryosuke Ogata, Yosuke Dotsu, Hiroaki Senju, Hiroshi Soda, Katsumi Nakatomi, Fumiko Hayashi, Nanae Sugasaki, Akitoshi Kinoshita, Hiroshi Muk |
Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1. Clinical pharmacokinetics 2023 9 . Mirjam de With, Leni van Doorn, Esmay Kloet, Anne van Veggel, Maja Matic, Micha J de Neijs, Esther Oomen-de Hoop, Esther van Meerten, Ron H N van Schaik, Ron H J Mathijssen, Sander Bi |
Overall Survival, BRAF, RAS, and MSI Status in Patients Who Underwent Cetuximab After Refractory Chemotherapy for Metastatic Colorectal Cancer. Journal of gastrointestinal cancer 2023 8 . Florinda A Santos, Rui Manuel Reis, Lucas C Barroti, Allan A L Pereira, Marcus M Matsushita, Ana Carolina de Carvalho, José Guilherme Datorre, Gustavo N Berardinelli, Raphael L C Arau |
The BEETS (JACCRO CC-18) trial: an observational and translational study of BRAF-mutated metastatic colorectal cancer. Future oncology (London, England) 2023 7 19 (17): 1165-1174. Chiaki Inagaki, Ryo Matoba, Satoshi Yuki, Manabu Shiozawa, Akihito Tsuji, Eisuke Inoue, Kei Muro, Wataru Ichikawa, Masashi Fujii, Yu Sunaka |
FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAF-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023 6 JCO2201420. Sebastian Stintzing, Kathrin Heinrich, David Tougeron, Dominik Paul Modest, Ingo Schwaner, Jan Eucker, Rudolf Pihusch, Martina Stauch, Florian Kaiser, Christoph Kahl, Meinolf Karthaus, Christian Müller, Christof Burkart, Anke Reinacher-Schick, Stefan Kasper-Virchow, Ludwig Fischer von Weikersthal, Beate Krammer-Steiner, Gerald Wolfgang Prager, Julien Taieb, Volker Heinema |
Irinotecan- vs. Oxaliplatin-Based Doublets in KRAS-Mutated Metastatic Colorectal Cancer-A Multicentre Propensity-Score-Matched Retrospective Analysis. Cancers 2023 6 15 (11): . Vincenzo Formica, Cristina Morelli, Veronica Conca, Maria Alessandra Calegari, Jessica Lucchetti, Emanuela Dell'Aquila, Marta Schirripa, Marco Messina, Lisa Salvatore, Federica Lo Prinzi, Giovanni Dima, Giovanni Trovato, Silvia Riondino, Mario Roselli, Ferdinandos Skoulidis, Hendrik-Tobias Arkenau, Chiara Cremoli |
Predictive Value of ABCC2 and UGT1A1 Polymorphisms on Irinotecan-Related Toxicities in Patients with Cancer. Genetic testing and molecular biomarkers 2023 5 27 (5): 133-141. Zineb Aoullay, Andrew Smith, Meriem Slaoui, Ihssane El Bouchikhi, Hassan Ghazal, Najib Al Idrissi, Bouchra Meddah, Kara L Lynch, Yahia Cherrah, Alan H B |
Exploration of the immunogenetic landscape of hyperprogressive disease after combined immunotherapy in cancer patients. iScience 2023 5 26 (6): 106720. Caifeng Gong, Wen Zhang, Yongkun Sun, Jianzhong Shou, Zhichao Jiang, Tianyi Liu, Shengzhou Wang, Jun Liu, Ying Sun, Aiping Zh |
A single-center retrospective analysis of the efficacy and safety of a modified regimen of irinotecan plus S-1 (IRIS) with molecular targeting agents as second-line chemotherapy in Japanese patients with recurrent or nonresectable colorectal cancer. Journal of gastrointestinal oncology 2023 5 14 (2): 663-675. Shigeo Higami, Masaya Mukai, Daiki Yokoyama, Syuji Uda, Rin Abe, Nana Mamuro, Kyoko Kishima, Sayuri Hasegawa, Takayuki Tajima, Eiji Nomura, Hiroyasu Makuuc |
Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma. Cancer research communications 2023 3 2 (11): 1418-1425. Christenson Eric S, Lim Su Jin, Durham Jennifer, De Jesus-Acosta Ana, Bever Katherine, Laheru Daniel, Ryan Amy, Agarwal Parul, Scharpf Robert B, Le Dung T, Wang H |
Effects of KMT2D mutation and its exon 39 mutation on the immune microenvironment and drug sensitivity in colorectal adenocarcinoma. Heliyon 2023 2 9 (2): e13629. Liu Chuan, Jin Yuzhi, Zhang Hangyu, Yan Junrong, Guo Yixuan, Bao Xuanwen, Zhao Pe |
Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pancreatic Ductal Adenocarcinoma: A Multicenter, Retrospective Cohort Study (HGCSG2101). Journal of clinical medicine 2023 2 12 (4): . Harada Kazuaki, Yamamura Takahiro, Muto Osamu, Nakamura Michio, Sogabe Susumu, Sawada Kentaro, Nakano Shintaro, Yagisawa Masataka, Muranaka Tetsuhito, Dazai Masayoshi, Tateyama Miki, Kobayashi Yoshimitsu, Kato Sosuke, Hatanaka Kazuteru, Kawamoto Yasuyuki, Yuki Satoshi, Sakata Yuh, Sakamoto Naoya, Komatsu Yoshi |
UGT1A1 genotype-guided irinotecan dosing during neoadjuvant chemoradiotherapy for locally advanced rectal cancer: A prospective analysis of SN-38 concentration. International journal of cancer 2023 12 . Pei-Cheng Jiang, Shuo-Wen Wang, Chao Li, Jin Fan, Ji Z |
Real-World Outcomes of First-Line FOLFIRI Plus Bevacizumab with Irinotecan Dose Escalation versus FOLFOXIRI Plus Bevacizumab in BRAF-Mutant Metastatic Colorectal Cancer: The Preliminary Data from a Single-Center Observational Study. Medicina (Kaunas, Lithuania) 2023 12 59 (12): . Hsiang-Lin Tsai, Ching-Wen Huang, Yen-Cheng Chen, Wei-Chih Su, Tsung-Kun Chang, Po-Jung Chen, Ching-Chun Li, Yu-Tang Chang, Jaw-Yuan Wa |
A phase-II study based on dose adjustment according to UGT1A1 polymorphism: is irinotecan underdosed in first-line FOLFIRI regimen for mCRC? Cancer chemotherapy and pharmacology 2023 11 . Angeline Ginzac, Emilie Thivat, Caroline Petorin, Damien Richard, Pauline Herviou, Ioana Molnar, Hervé Devaud, Isabelle Creveaux, Florent Ferrer, Nicolas Authier, Marine Jary, Denis Pezet, Xavier Duran |
Anti-epidermal growth factor receptor treatment for patients with NeoRAS wild-type metastatic colorectal cancer: a case report of two cases. Therapeutic advances in medical oncology 2023 11 15 17588359231216090. Kazuaki Harada, Satoshi Yuki, Yasuyuki Kawamoto, Takeaki Nakamura, Shiho Kaneko, Koichi Ishida, Naoya Sakamoto, Yoshito Komat |
Temporal offset association between the number of irinotecan-related adverse reactions and pharmacogenomic studies: A cross-correlation analysis. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society 2023 1 31 (1): 180-183. Kong Lingti, Rong Li, Xie Mengyuan, Wang Muh |
TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes. Annals of oncology : official journal of the European Society for Medical Oncology 2024 1 . Y Loriot, D P Petrylak, A Rezazadeh Kalebasty, A Fléchon, R K Jain, S Gupta, M Bupathi, P Beuzeboc, P Palmbos, A V Balar, C E Kyriakopoulos, D Pouessel, C N Sternberg, J Tonelli, M Sierecki, H Zhou, P Grivas, P Barthélémy, S T Taga |
A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Regorafenib in Patients with Metastatic Colorectal Cancer Who Have Failed First-Line Therapy. International journal of molecular sciences 2024 1 25 (1): . Karen Gambaro, Maud Marques, Suzan McNamara, Mathilde Couetoux du Tertre, Cyrla Hoffert, Archana Srivastava, Anna Schab, Thierry Alcindor, Adrian Langleben, Lucas Sideris, Mahmoud Abdelsalam, Mustapha Tehfe, Felix Couture, Gerald Batist, Petr Kav |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 22, 2024
- Content source: